BioCentury
ARTICLE | Company News

Vanda sues FDA over 'unnecessary' dog testing requirement

February 8, 2019 5:47 PM UTC

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) filed suit against FDA requesting a federal court lift a partial clinical hold the agency placed on tradipitant after Vanda refused to conduct a nine-month dog toxicity study.

In an open letter, Vanda called on drug companies to join it in asking FDA to change its policy of routinely requiring "unnecessary" chronic dog studies. "Killing animals without a scientifically justified purpose is unethical and inhumane," it wrote...